title: The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge.
abstract: DNA- and protein- based vaccines against cutaneous leishmaniasis due to Leishmania major were evaluated using a challenge model that more closely reproduces the pathology and immunity associated with sand fly-transmitted infection. C57BL/6 mice were vaccinated s.c. with a mixture of plasmid DNAs encoding the Leishmania Ags LACK, LmSTI1, and TSA (AgDNA), or with autoclaved L. major promastigotes (ALM) plus rIL-12, and the mice were challenged by inoculation of 100 metacyclic promastigotes in the ear dermis. When challenged at 2 wk postvaccination, mice receiving AgDNA or ALM/rIL-12 were completely protected against the development of dermal lesions, and both groups had a 100-fold reduction in peak dermal parasite loads compared with controls. When challenged at 12 wk, mice vaccinated with ALM/rIL-12 maintained partial protection against dermal lesions and their parasite loads were no longer significantly reduced, whereas the mice vaccinated with AgDNA remained completely protected and had a 1000-fold reduction in dermal parasite loads. Mice vaccinated with AgDNA also harbored few, if any, parasites in the skin during the chronic phase, and their ability to transmit L. major to vector sand flies was completely abrogated. The durable protection in mice vaccinated with AgDNA was associated with the recruitment of both CD8(+) and CD4(+) T cells to the site of intradermal challenge and with IFN-gamma production by CD8(+) T cells in lymph nodes draining the challenge site. These data suggest that under conditions of natural challenge, DNA vaccination has the capacity to confer complete protection against cutaneous leishmaniasis and to prevent the establishment of infection reservoirs.
authors: Laboratory of Parasitic Diseases and Laboratory of Clinical Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
authors: S
authors: S
authors: Méndez
authors: S
authors: S
authors: Gurunathan
authors: S
authors: S
authors: Kamhawi
authors: Y
authors: Y
authors: Belkaid
authors: M A
authors: MA
authors: Moga
authors: Y A
authors: YA
authors: Skeiky
authors: A
authors: A
authors: Campos-Neto
authors: S
authors: S
authors: Reed
authors: R A
authors: RA
authors: Seder
authors: D
authors: D
authors: Sacks
mesh_terms: D000818:Animals; D000953:Antigens, Protozoan / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use; D000954:Antigens, Surface / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use; D016054:DNA, Protozoan / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use; D004306:Dose-Response Relationship, Immunologic; D006968:Hypersensitivity, Delayed / Q000276:immunology; D007113:Immunity, Innate; D007115:Immunization Schedule; D007117:Immunization, Secondary; D007156:Immunologic Memory; D007271:Injections, Intradermal; D007303:Insect Vectors / Q000469:parasitology; D018664:Interleukin-12 / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use; D018320:Leishmania major / Q000235:genetics / Q000254:growth & development / Q000276:immunology*; D016773:Leishmaniasis, Cutaneous / Q000276:immunology* / Q000473:pathology / Q000517:prevention & control* / Q000635:transmission; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D015800:Protozoan Proteins / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use*; D016052:Protozoan Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use*; D011576:Psychodidae / Q000469:parasitology; D019444:Vaccines, DNA / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use; D014643:Variant Surface Glycoproteins, Trypanosoma
chemical_list: D000953:Antigens, Protozoan; D000954:Antigens, Surface; D016054:DNA, Protozoan; D015800:Protozoan Proteins; D016052:Protozoan Vaccines; D019444:Vaccines, DNA; D014614:Vaccines, Synthetic; D014643:Variant Surface Glycoproteins, Trypanosoma; C070842:trypomastigote specific surface antigen; D018664:Interleukin-12